Tsutomu Kawaguchi

Abemaciclib as both first- and second-line therapy was associated with sustained treatment duration in Japanese patients, and particularly, first-line abemaciclib plus NSAI followed by second-line abemaciclib plus fulvestrant may be a clinically meaningful treatment option.